Metabolomic profile in pregnant women with fetal growth restriction

1. Вишнякова П.А., Суханова Ю.А., Микаелян А.Г., Булатова Ю.С., Пятаева С.В., Балашов И.С., Боровиков П.И., Тетруашвили Н.К., Высоких М.Ю. Синдром задержки роста плода и маркеры митохондриальной дисфункции. Акушерство и гинекология. 2018; 6: 31–6. [Vishnyakova P.A., Sukhanova Yu.A., Mikaelyan A.G., Bulatova Yu.S., Pyataeva S.V., Balashov I.S., Borovikov P.I., Tetruashvili N.K., Vyssokikh M.Yu. Fetal growth restriction and markers for mitochondrial dysfunction. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (6): 31–6. (in Russian)]. doi:10.18565/aig.2018.6.31-36
2. Unterscheider J., Daly S., Geary M.P., Kennelly M.M., McAuliffe F.M., O’Donoghue K., et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol. 2013; 208(4): 290.e1-6. doi: 10.1016/j.ajog.2013.02.007
3. Cruz-Lemini M., Crispi F., Van Mieghem T., Pedraza D., Cruz-Martínez R., Acosta-Rojas R., et al. Risk of perinatal death in early-onset intrauterine growth restriction according to gestational age and cardiovascular Doppler indices: a multicenter study. Fetal Diagn Ther. 2012; 32(1–2): 116–22. doi: 10.1159/000333001.
4. Balasuriya C.N.D., Stunes A.K., Mosti M.P., Schei B., Indredavik M.S., Hals I.K., et al. Metabolic outcomes in adults born preterm with very low birth weight or small for gestational age at term: a cohort study. J Clin Endocrinol Metab. 2018;103(12): 4437–46. doi: 10.1210/jc.2018-00464
5. Lee A.C., Kozuki N., Cousens S., Stevens G.A., Blencowe H., Silveira M.F., et al. Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasets. BMJ. 2017; 358:j3677. doi: 10.1136/bmj.j3677
6. Dessì A., Atzori L., Noto A., Visser G.H., Gazzolo D., Zanardo V., et al. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. J Matern Fetal Neonatal Med. 2011; 24 Suppl 2: 35–9. doi: 10.3109/14767058.2011.605868
7. Dessì A., Marincola F.C., Pattumelli M.G., Ciccarelli S., Corbu S., Ossicini C., et al. Investigation of the 1H-NMR based urine metabolomic profiles of IUGR, LGA and AGA newborns on the first day of life. J Matern Fetal Neonatal Med. 2014; 27 Suppl 2: 13–9. doi: 10.3109/14767058.2014.955674
8. Barberini L., Noto A., Fattuoni C., Grapov D., Casanova A., Fenu G., et al. Urinary metabolomics (GCMS) reveals that low and high birth weight infants share elevated inositol concentrations at birth. J Matern Fetal Neonatal Med. 2014; 27 Suppl 2: 20–6. doi: 10.3109/14767058.2014.954786
9. Metzger B.E., Lowe L.P., Dyer A.R., Trimble E.R., Chaovarindr U., et al. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008; 358(19): 1991–2002. doi: 10.1056/NEJMoa0707943
10. Chau J.F., Lee M.K., Law J.W., Chung S.K., Chung S.S. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J. 2005; 19(13): 1887–9. doi: 10.1096/fj.05-4192fje
11. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositl in women with PCOs: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7): 509–15. doi: 10.3109/09513590.2011.650660
12. Santamaria A., Giordano D., Corrado F., Pintaudi B., Interdonato M.L., Vieste G.D., et al. One-year effects of myo-inositol supplementation in post-menopausal women with metabolic syndrome. Climacteric. 2012; 15(5): 490–5. doi: 10.3109/13697137.2011.631063
13. Maitre L., Fthenou E., Athersuch T., Coen M., Toledano M.B., Holmes E., et al. Urinary metabolic profiles in early pregnancy are associated with preterm birth and fetal growth restriction in the Rhea mother-child cohort study. BMC Med. 2014;12:110. doi: 10.1186/1741-7015-12-110
14. Favretto D., Cosmi E., Ragazzi E., Visentin S., Tucci M., Fais P., et al. Cord blood metabolomics profiling in intrauterine growth restriction. Anal Bioanal Chem. 2012; 402(3): 1109–21. doi: 10.1007/s00216-011-5540-z
15. Sanz-Cortés M., Carbajo R.J., Crispi F., Figueras F., Pineda-Lucena A., Gratacós E. Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation. PLoS One. 2013; 8(12): e80121. doi: 10.1371/journal.pone.0080121
16. Liu J., Chen X.X., Li X.W., Fu W., Zhang W.Q. Metabolomic research on newborn infants with intrauterine growth restriction. Medicine (Baltimore) 2016; 95(17): e3564 doi: 10.1097/MD.0000000000003564
17. Visentin S., Crotti S., Donazzolo E., D’Aronco S., Nitti D., Cosmi E., et al. Medium chain fatty acids in intrauterine growth restricted and small for gestational age pregnancies. Metabolomics. 2017;13(05):1–9
18. Lindsay K.L., Hellmuth C., Uhl O., Buss C., Wadhwa P.D., Koletzko B., et al. Longitudinal metabolomics profiling of amino acids and lipids across healthy pregnancy. PLoS One. 2015; 10(12): e0145794. doi: 10.1371/journal.pone.0145794
19. Leite D., Cecatti J. New Approaches to Fetal Growth Restriction: The Time for Metabolomics Has Come. Rev Bras Ginecol Obstet. 2019; 41(7): 454–62. doi: 10.1055/s-0039-1692126

Received 01.10.2019

Accepted 04.10.2019